Gliomic Therapeutics
June 22, 2026
Theater 2
Type: Company Presentation
Focus Area:
Oncology
Gliomic is focused on providing new therapeutic options for large unmet needs in genetically-defined brain tumors. Our scientific founders, including Sam McBrayer PhD (UT Southwestern) and Bill Kaelin MD (Harvard; Nobel Prize 2019) discovered that IDH mutant brain tumors experience highly potent synthetic lethality when exposed to a DHODH inhibitor (far more potent than IDH inhibition itself). Working with experts in DHODH inhibitor development, they identified a highly potent, brain penetrant lead candidate, which shows highly selective cancer cell killing in vitro, consistent improvements in overall survival in gold standard xenograft models, and remarkable tolerability in animals. Rapid and straightforward development with 6 years to pivotal data and peak revenues estimated $3B from US alone. Unique competitive position, with composition of matter protection into the mid 2040's. Seeking Series A to fund IND and initial clinical trials.
Company HQ City:
New York
Company HQ State:
New York
Company HQ Country:
United States
Year Founded:
2025
Lead Product in Development:
GLIO-1
CEO
Duane Nash MD JD MBA
Development Phase of Lead Product
Pre-Clinical
When you expect your next catalyst update?
YE:2026
What is your next catalyst (value inflection) update?
2026 complete IND testing
2027 begin Phase 1b
2028 begin phase 2/3
2032 phase 3 data
Primary Speaker
)
)
)
){kind=logo}
){kind=logo}
)
)
){kind=logo}
){kind=logo}